Actively Recruiting
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2024-04-18
100
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy. Actuarial data however supports that approximately 20% of mCRC-LR patients can be cured without as much systemic chemotherapy. Prospective phase II-III trials also support that awaiting recurrence to initiate further metastases-targeted or systemic treatment may provide patients with longer overall survival while avoiding toxicities in those without recurrence.
CONDITIONS
Official Title
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients 18 years of age or older at consent
- Stage IV colon or rectal adenocarcinoma with liver-only metastases planned for partial hepatectomy with curative intent
- Liver metastases may be ablated by needle radio frequency or microwave as part of treatment
- Planned two-stage partial hepatectomies allowed
- Patients with lung micro nodules or intra-abdominal nodes/nodules not considered extra-hepatic metastases may be included
- Scheduled to receive FOLFOX-based pre-hepatectomy chemotherapy with or without additional agents like Irinotecan, anti-EGFR, or anti-VEGF drugs
- Willing and able to provide serial blood, tumor, and stool samples for research
- Primary tumor treatment per standard of care, including possible pre-operative radiotherapy for rectal cancer
- Post-operative adjuvant chemotherapy allowed per standard of care
- Consent to the Exactis Personalized my Treatment registry required
You will not qualify if you...
- Pregnant or breastfeeding patients
- Hereditary colorectal cancer such as familial colonic polyposis or Lynch syndrome
- Presence of any other concurrent cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
Research Team
W
Wiam Belkaid, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here